Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Neuraxpharm Arzneimittel GmbH

Latest From Neuraxpharm Arzneimittel GmbH

Neuraxpharm Vows Swift Appeal Over Pulled EU Tecfidera Generics

Neuraxpharm has vowed to rapidly challenge a legal decision that has seen generic rivals to Biogen’s Tecfidera (dimethyl fumarate) multiple sclerosis treatment pulled from the market in Europe.

Legal Issues Intellectual Property

European Regulator Pulls Marketing Authorizations For Tecfidera Generics

In a blow to several generics firms – albeit one telegraphed by a decision handed down nine months ago – the European Commission has ordered the removal of marketing authorizations for generic versions of Biogen’s MS brand, Tecfidera.

Regulation Generic Drugs

TG Therapeutics Briumvi Deal Fails To Impress The Market

Linking up with Germany’s Neuraxpharm to sell the multiple sclerosis drug Briumvi in Europe and elsewhere has gone down badly with investors but the bashing that TG Therapeutics’ shares has taken seems excessive.

Deals Sales & Earnings

Neuraxpharm Expands Into Brazil And Mexico

In a two-pronged push into Latin America, European CNS specialist Neuraxpharm has set up operations in Mexico and Brazil, with the latter bolstered by the acquisition of local player Libber Pharma.

Strategy Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer